Abstract
From January 1988 to January 1993, 45 patients with unresectable advanced hepatocellular carcinoma (HCC) were treated with a new combination therapy consisting of arterial infusion chemotherapy and TAE. The combination therapy was performed according to our treatment schedule as follows: two courses of arterial infusion chemotherapy were given first, and then transcatheter arterial embolization (TAE) using a mixture of Lipiodol and cisplatin powder was performed. Two arterial infusion chemotherapeutic regimens were employed: EPF (etoposide, cisplatin, and 5-fluorouracil) and EAP (etoposide, Adriamycin or Epi-adriamycin, and cisplatin). The anticancer drugs were infused through a catheter inserted into the proper or common hepatic artery. Assessment was made of the anticancer effect and survival rate of each treatment method. The response to each therapy was evaluated on the basis of CT performed prior to and after the treatment. In the EPF·TAE group, the response rate was about 46%, whereas in the EAP·TAE group it was 48%. Overall, 21 of 45 patients attained a regression rate of 50% or more. Furthermore, daughter nodules decreased in size or disappeared in about 67% of 15 patients. Additionally, tumor thrombi tended to show a similar response. In all of the cases, the average duration of survival was 30.3 months, and the 1-year survival value was 68%, the 2-year survival value was 44%, and the 3-year survival value was 35%. These results were superior to those obtained with TAE therapy alone.
Similar content being viewed by others
References
Japan Society for Cancer Therapy (1986) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy (in Japanese). J Jpn Soc Cancer Ther 21: 929
Liver Cancer Study Group of Japan (1987) The general rules for the clinical and pathological study of primary liver cancer (in Japanese). Kanehara & Co., Tokyo
Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with Adriamycin. Cancer 51: 206
Nagasue N, Yukaya H (1989) Liver resection for hepatocellular carcinoma: results from 150 consecutive patients. Cancer Chemother Pharmacol 23 [Suppl]: S78
Nakamura K, Takashima S, Takada K, Fujimoto K, Kaminou T, Nakatsuka H, Minakuchi K, Onoyama Y (1992) Clinical evaluation of intermittent arterial infusion chemotherapy with an implanted reservoir for hepatocellular carcinoma. Cancer Chemother Pharmacol 31 [Suppl I]: S93
Quinn JJ, Altman AJ, Robinson T, Cooke RW, Hight DW, Foster JH (1985) Adriamycin and cisplatin for hepatoblastoma. Cancer 56: 1926
Sakurai M, Okamura J, Kuroda C (1984) Transcatheter chemoembolization effective for treating hepatocellular carcinoma. Cancer 54: 387
Sugiura N, Takara K, Ohto M, Okuda K, Hirooka N (1983) Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. Acta Hepatol Jpn 24: 920
Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397
Yodono H, Saito Y, Saikawa Y, Midorikawa H, Yokoyama Y, Takekawa SD (1989) Combination chemoembolization therapy for hepatocellular carcinoma mainly using cisplatin (CDDP). Cancer Chemother Pharmacol 23 [Suppl]: S42
Yodon H, Tarusawa K, Sasaki T, Kanehira J, Saito Y, Takahashi S, Kimura T, Nishi N, Nakamura Y, Takekawa SD (1989) A case with hepatocellular carcinoma effectively treated by intra-arterial infusion of CDDP and other agents. Jpn J Cancer Chemother 16: 3265
Yodono H, Sasaki T, Tarusawa K, Midorikawa H, Saito Y, Takekawa SD (1992) Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. Cancer Chemother Pharmacol 31 [Suppl I]: S89
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yodono, H., Takekawa, S.D., Tarusawa, K. et al. Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE). Cancer Chemother. Pharmacol. 33 (Suppl 1), S79–S83 (1994). https://doi.org/10.1007/BF00686673
Issue Date:
DOI: https://doi.org/10.1007/BF00686673